Beta adrenergic blockers
PreclinicalSmall molecule
Beta adrenergic blockers is one of 17 small molecule programs targeting Cardiovascular. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Cardiovascular
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Ozempic
Novo NordiskApproved
Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cialis
Eli LillyPhase 3
Letairis
GileadPhase 3
Farxiga
AstraZenecaPhase 3
Metformin XR
AstraZenecaPhase 3
Xarelto
WWim Janssens
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Beta adrenergic blockers. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details